ReviewCureus2025
The Impact of Commonly Used Medications on Erectile Dysfunction: Which Drugs Deserve Particular Attention?
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sexual dysfunction and distress in patients with depressive disorders at a tertiary care hospital in Riyadh, Saudi Arabia: a cross-sectional study.BMC psychiatry · 2026Article
- E-cigarettes and erectile dysfunction: biological mechanisms and research challenges.International journal of impotence research · 2026Review
- Improving Sexual Dysfunction with Cinnamon Leaf Extract and Nanoemulsion by Using a Rat Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erectile dysfunction (ED) is a common but often underrecognized side effect of numerous medications prescribed for chronic conditions, particularly cardiovascular, psychiatric, and neurological disorders. This article reviews the impact of various drug classes on erectile function, focusing on mechanisms and clinical implications. Antipsychotics, widely used in schizophrenia, frequently cause ED through dopamine inhibition and increased prolactin levels, affecting libido and erectile capacity. Beta-blockers, especially older non-selective agents, contribute to ED by causing vascular constriction and hormonal alterations, while newer agents like nebivolol may improve erectile function via nitric oxide release. Diuretics, particularly thiazides, show mixed evidence regarding their effect on erectile function, though aldosterone receptor antagonists such as spironolactone are linked to antiandrogenic side effects. Centrally acting antihypertensives, antiepileptics, non-steroidal anti-inflammatory drugs (NSAIDs), lithium, and opioids also play significant roles in sexual dysfunction, primarily through hormonal disruption, vascular effects, and central nervous system pathways. Notably, opioids exert profound effects on the hypothalamic-pituitary-gonadal axis, leading to high rates of ED in younger men. In contrast, renin-angiotensin system inhibitors and calcium channel blockers generally exhibit neutral or beneficial effects on sexual function. Understanding these drug-related risks is crucial for clinicians to tailor therapies that minimize sexual side effects, thereby enhancing patient adherence and overall quality of life. Further research is warranted to clarify mechanisms and develop effective management strategies for medication-induced ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.